OncoMatch/Clinical Trials/NCT05636618
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Is NCT05636618 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including [203Pb]VMT-α-NET and [212Pb]VMT-α-NET for neuroendocrine tumors unresectable.
Treatment: [203Pb]VMT-α-NET · [212Pb]VMT-α-NET — This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroendocrine Tumor
Pancreatic Cancer
Meningioma
Biomarker criteria
Required: SSTR2 expression (positive)
Demonstration of lesional SSTR expression: (a) For NETs: using an FDA-approved somatostatin receptor PET imaging agent, e.g. [68Ga]DOTATATE, [64Cu]DOTATATE, or [68Ga]DOTATOC (b) For meningioma: using a standard-of-care SSTR PET imaging agent within 45 days of enrollment
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic PRRT ([90Y]DOTATATE, [90Y]DOTATOC, [177Lu]DOTATATE)
Prior treatment with systemic PRRT based therapies (i.e., [90Y] DOTATATE/DOTATOC or [177Lu] DOTATATE)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Jacksonville, Florida
- Biogenix Molecular · Miami, Florida
- The University of Chicago · Chicago, Illinois
- University of Iowa · Iowa City, Iowa
- University of Kentucky · Lexington, Kentucky
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05636618 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic PRRT disqualifies patients from enrollment.
Does this trial require SSTR2?
Yes, SSTR2 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 90 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify